Wednesday, October 31, 2007

Find the nearst Pharmaceutical Company...

MRSA found at city college
BY SARAH HOFIUS HALL
STAFF WRITER
10/31/2007

email this storyEmail to a friendprinter friendlyPrinter-friendly
# Staphylococcus aureus, often referred to simply as “staph,” is commonly carried on the skin or in the nose of healthy people. Sometimes, staph can cause an infection. Staph is among the most common causes of skin infections. Most of these skin infections are minor and can be treated without antibiotics.

# Methicillin-resistant Staphylococcus aureus (MRSA) is a type of staph that is resistant to certain antibiotics. While 25 percent to 30 percent of the population carries staph, only about 1 percent normally carries MRSA.

# Most MRSA infections are treated by administering good wound and skin care. In some instances, antibiotics are also used to treat MRSA.

# Frequent hand washing is the best way to prevent getting and spreading staph and MRSA.
A Lackawanna College football player has been diagnosed with a MRSA staph infection, college officials confirmed Tuesday.

“Obviously it’s a cause for concern,” Lackawanna spokesman Kevin O’Hara said.

MRSA is an infection caused by Staphylococcus aureus bacteria, commonly called “staph.” Methicillin-resistant Staphylococcus aureus, or MRSA, is resistant to many antibiotics and in severe cases can be fatal. Staph bacteria are generally harmless, unless they enter the body through a cut or wound.

Several local schools have recently reported cases of MRSA, including Dunmore, Wyoming Area and Wilkes-Barre Area. Those schools have been disinfected, and no additional cases have been reported.

The University of Scranton had one student with MRSA earlier this semester, and that student was successfully treated with antibiotics, spokesman Stan Zygmunt said Tuesday.

At Lackawanna, areas of the college will be disinfected today, and students have been notified of the case.

For the college and school districts that have no reported cases of MRSA, steps are being taken to inform students of the infections.

Lackawanna College officials first learned of the football player’s infection Friday, after his doctor cleared him to go back to school. Football players were notified of the issue at that time, and the student had a relapse over the weekend. After the relapse, officials felt it necessary to alert all students. He has not returned to school and is now at home, Mr. O’Hara said.

Notices have been posted in dorms and in restrooms about proper hygiene, and all students were sent a memo about the situation on Tuesday, Mr. O’Hara said. The roommates of the infected student have been temporarily moved until a proper room cleaning can be done.

Powered by ScribeFire.

Monday, October 29, 2007

At least I know what I'm getting.



I don't agree with Ron Paul on most issues... But you know what? At least I know where we differ. I have to vote for the honest person.

Thursday, October 18, 2007

Happy Birthday to me!

Happy Birthday to me!
Happy Birthday to me!
Happy Birthday il128!
Happy Birthday to me!

TERRE HAUTE, Ind. (AP)--Pfizer Inc. (PFE) has halted production of the inhaled diabetes drug at its western Indiana plant following the company's decision to drop the insulin drug due to disappointing sales, a Pfizer spokesman said Thursday.

The New York-based company has placed about 600 of the 750 workers at its Vigo County plant - Pfizer's sole Exubera production center - on paid leave as it weighs the plant's future, said company spokesman Rick Chambers.

For now, he said the plant's 150 other workers will continue making two antibiotics.

"We've not made a decision on the future of the plant. We're going to take some time to review our options on it," Chambers said.

Pfizer, the world's largest pharmaceutical company, had invested more than $ 300 million in the past five years on its Vigo County plant, south of Terre Haute. Over the past year it had hired about 400 people, boosting the plant's work force to more than 750.

Pfizer said Thursday that its third-quarter profit plunged due to a $2.8 billion charge to end its investment in Exubera, and lower sales of blockbuster cholesterol drug Lipitor.

The company earned $761 million, or 11 cents per share, down sharply from profit of $3.36 billion, or 46 cents per share, during the same period a year ago. Excluding one-time charges, Pfizer said it earned 58 cents per share in the latest period.

Revenue fell 2% to $11.99 billion from $12.28 billion a year earlier.

Jeff Kindler, Pfizer's chairman and chief executive, said the company initially had "high expectations" for Exubera, but the drug proved not to be popular with diabetes patients.

"Despite our best efforts, Exubera has failed to gain the acceptance of patients and physicians. We have therefore concluded that further investment in this product is unwarranted," he said.

Pfizer received federal approval in January 2006 to market Exubera, the first new way of delivering insulin since the discovery of the hormone in the 1920s. Pfizer jointly developed the drug and dispenser with Sanofi-Aventis SA ( 12057.FR) and Nektar Therapeutics (NKTR).

Exubera was the first inhalable version of insulin, which offered millions of adult diabetics an alternative to some of the injections they now endure.